Ivy Brain Tumor Center, SonALAsense and Insightec Announce the First Patient Dosed in First-in-Human Clinical Trial of Noninvasive Sonodynamic Therapy for the Treatment of Brain Cancer
March 30, 2021 08:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, March 30, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, has...
Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy
March 24, 2021 18:00 ET
|
Enochian Biosciences, Inc.
LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in...
First Patient Treated in Ivy Brain Tumor Center’s Phase 0 Clinical Trial of Pamiparib in Newly Diagnosed and Recurrent Glioblastoma
March 10, 2021 09:32 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, March 10, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the first patient has been treated in a Phase 0 clinical trial of pamiparib...
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
December 28, 2020 08:00 ET
|
CNS Pharmaceuticals, Inc.
HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary...
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
December 21, 2020 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Ivy Brain Tumor Center Initiates Phase 0 Clinical Trial with BeiGene for Newly Diagnosed and Recurrent Glioblastoma
December 16, 2020 07:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Dec. 16, 2020 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute today announced the opening of a Phase 0 clinical trial for patients with newly diagnosed...
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy
November 24, 2020 08:00 ET
|
CNS Pharmaceuticals, Inc.
HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary...
NX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)
November 17, 2020 14:12 ET
|
NX Development Corp.
Lexington, KY, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced the enrollment of the first...
Telix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
November 01, 2020 23:11 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and HONG KONG, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into a strategic licence and...
Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma
October 16, 2020 11:00 ET
|
Connectyx Technologies Holdings Group, Inc
Boca Raton, FL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...